NCT04250129 (NEOSENTITURK) is a clinical trial in Sentinel Lymph Node, sponsored by Federation of Breast Diseases Societies.

Who is sponsoring NCT04250129?

NCT04250129 is sponsored by Federation of Breast Diseases Societies.

What condition does NCT04250129 study?

NCT04250129 studies Sentinel Lymph Node.

Is NCT04250129 still recruiting?

NCT04250129 is currently status unknown. Last updated 31 January 2020.

Last reviewed 2020-01-31 · How we verify

NCT04250129: NEOSENTITURK

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

SENTINEL LYMPH NODE BIOPSY AFTER NEOADJUVANT CHEMOTHERAPY

Status unknown Last updated 31 January 2020

What this trial tests

trial in Sentinel Lymph Node in 500 participants. Status unknown.

Timeline

31 January 2018

Primary endpoint
31 December 2021

31 January 2023

Quick facts

Lead sponsor	Federation of Breast Diseases Societies
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	500
Start date	31 January 2018
Primary completion	31 December 2021
Estimated completion	31 January 2023
Sites	3 locations across Turkey (Türkiye)

Conditions studied

Sentinel Lymph Node — all drugs for Sentinel Lymph Node →

Sponsor

Federation of Breast Diseases Societies

Who can join

Adults 18 to 70, female only, with Sentinel Lymph Node. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Omitting axilary lymph node dissection (ALND) following SLNB with residual cancer in patients with locally advanced disease after neoadjuvan chemotherapy (NAC) is still controversial. In this study, the investigators evaluated factors affecting local recurrence and outcome in patients with locally advanced breast cancer (LABC), who underwent sentinel lymph node (SLN) with or without ALND after NAC.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

De-Escalation of Nodal Surgery in Clinically Node-Positive Breast Cancer.
Cabioglu N, Koçer HB, Karanlik H, Gülçelik MA, et al · · 2025 · cited 17× · PMID 39745737 · DOI 10.1001/jamasurg.2024.5913
Combined analysis of the MF18-02/MF18-03 NEOSENTITURK studies: ypN-positive disease does not necessitate axillary lymph node dissection in patients with breast cancer with a good response to neoadjuvant chemotherapy as long as radiotherapy is provided.
Muslumanoglu M, Cabioglu N, Igci A, Karanlık H, et al · · 2025 · cited 8× · PMID 39476303 · DOI 10.1002/cncr.35610
Breast Cancer Recurrence in Initially Clinically Node-Positive Patients Undergoing Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in the NEOSENTITURK-Trials MF18-02/18-03.
Cabioglu N, Karanlik H, Igci A, Muslumanoglu M, et al · · 2025 · cited 7× · PMID 39623189 · DOI 10.1245/s10434-024-16472-6
The American Society of Breast Surgeons Official Proceedings, Volume XXII 2021 Annual Meeting Scientific Session Abstracts.
· 2021 · cited 4× · PMID 33948775 · DOI 10.1245/s10434-021-10068-0
ASO Author Reflections: Nodal Recurrence Is Rare in Patients with cN+/ycN0 Breast Cancer after Neoadjuvant Chemotherapy Regardless of the Extent of Axillary Surgery or Nodal Pathology in the NEOSENTITURK-Trials MF18-02/18-03 Provided Regional Nodal Irradiation Is Administered.
Cabioglu N, Karanlik H, Igci A, Muslumanoglu M, et al · · 2025 · cited 1× · PMID 39653946 · DOI 10.1245/s10434-024-16651-5

Verify or expand the search:

Other recruiting trials for Sentinel Lymph Node

Currently open trials in the same condition.

NCT07040657 — Comparison of Two-Position and Four-Position Cervical Injection Techniques for Sentinel Lymph Node Mapping in Endometria · NA · recruiting
NCT07154563 — Rapid Assessment of Sentinel Lymph Node Metastasis Status Using a Pan-CK-targeting NIR-II Fluorescent Probe in Breast Ca · recruiting
NCT06652672 — Sentinel Node and Organ-sparing Surgery in Stage I Colon Carcinoma · NA · recruiting
NCT06713161 — Tumor-Targeted-NIR-II Fluorescent Molecular Probes for the Identification of Breast Cancer Tissue and SLN Metastatic Sta · recruiting
NCT06259513 — Omission of Axillary Surgery in Breast Cancer Patients · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04250129 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Federation of Breast Diseases Societies
Last refreshed: 31 January 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04250129.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing